Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND Merck announced today outcomes from a new non-inferiority trial of an antiemetic program containing fosaprepitant dimeglumine administered as an individual intravenous 150-mg dose in conjunction with a 5-HT3 antagonist and dexamethasone weighed against a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving a first cycle of cisplatin-based chemotherapy. The routine comprising 150 mg fosaprepitant dimeglumine was not inferior to the regimen with oral aprepitant. Results of the study, known as Convenience-017, will be presented on June 8th at the 2010 American Culture of Clinical Oncology annual meeting in Chicago, during a dialogue on the poster titled ‘Phase III randomized double-blind research of single-dosage fosaprepitant for prevention of cisplatin-induced nausea and vomiting drastic action more info .D., Professor of Pharmacology and Medication, University of Vermont. ‘These findings are essential because prevention of CINV can be a major concern, and this formulation of EMEND may potentially provide dosing flexibility to avoid CINV.’ Presently, EMEND is authorized as part of a three-day regimen for preventing acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic and highly emetogenic cancers chemotherapy, including high-dose cisplatin. Related StoriesMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer patientsMultigene check performed on tumor can recognize breast cancer individuals who can safely avoid chemotherapyVA Medical center performs first effective heated chemotherapy bath on a patient with mesotheliomaIn the analysis, 71.9 % of patients who received an antiemetic regimen that included a single, 150 mg dose of fosaprepitant , ondansetron 32 mg IV, and dexamethasone 12 mg orally on Day 1, and dexamethasone 8 mg orally on Day 2, and dexamethasone 8 mg orally twice daily on Days 3 and 4 achieved a complete response, thought as no vomiting and no use of rescue medication, in the overall phase of chemotherapy compared to 72.3 % of these receiving an antiemetic regimen containing a three-time oral regimen of EMEND . Furthermore, 74.3 % of patients treated with the regimen containing the single, 150 mg dosage of fosaprepitant achieved a complete response in the delayed phase , compared to 74.2 % of individuals treated with a regimen containing a three-day time regimen of EMEND. . The entire incidence and types of adverse events were consistent between your two treatment groups generally. The most regularly reported drug-related medical adverse events in both group receiving a single, 150 mg dosage of fosaprepitant and the group getting oral EMEND were asthenia , constipation, anorexia, diarrhea and nausea. Source Merck.
Antidepressants may increase heart attack or stroke risk in men: Study By Dr Ananya Mandal, MD A new study shows that men taking antidepressants might be at risk for atherosclerosis, which can increase the risk of a coronary attack or stroke. The small study revealed that antidepressants had been associated with in regards to a 5 % increase in the thickness of the large artery in the neck known as the carotid artery, which carries blood to the brain, the researchers from Emory University stated. Yet experts not involved with the analysis noted that it didn’t prove a cause-and-effect romantic relationship between antidepressant use and heart difficulty, and added that depression itself can raise the risk of cardiovascular problems. Dr. Gregg C. Amit Shah, a cardiology fellow at Emory. Shah is definitely a researcher dealing with Viola Vaccarino, seat of the Division of Epidemiology at Emory’s Rollins College of Public Wellness. The group collected data on 513 middle-aged male twins who had been section of the Vietnam Period Twin Registry. Sixteen % of the guys were taking antidepressants, and of the, 60 % were taking selective serotonin reuptake inhibitors , such as for example Prozac, Zoloft and Lexapro. Others were taking older antidepressants. The thickness was measured by The researchers of the carotid artery – called carotid intima-mass media thickness. The study authors discovered that a twin taking an antidepressant acquired a larger intima-media thickness than a brother not taking the medicines. The finding held true, of the antidepressant used regardless, the researchers said. Researchers came to the conclusion after adjusting for age, diabetes, blood pressure, previous or current smoking, cholesterol and weight. Other elements weighed included depressive symptoms, history of major major depression and heart disease, alcohol and coffee use, statin use, physical activity, education and employment, the researchers said. Related StoriesResearch finding could lead to new treatment to promote brain repair, useful recovery after strokeResearchers associate neuroimaging data with reading deficits in individuals with left-sided strokePacemakers can detect AF and enable initiation of anticoagulation for stroke preventionThey explain that since each additional year of life is associated with a small upsurge in intima-media thickness, a brother taking antidepressants is 4 years older than the brother not taking antidepressants physically, Shah’s team contended. They also said that a good small upsurge in intima-media thickness can raise the risk of a coronary attack or stroke by 1.8 %. The reason for this finding is not clear still. These drugs increase levels of the brain chemicals norepinephrine and serotonin, which are low in depressed individuals often. Shah said increased levels of these chemicals may cause arteries to tighten, and this may lead to reduced blood flow to organs and higher blood pressure, which is a risk factor for atherosclerosis. Dr. Dominique L. Musselman, a co-employee professor of clinical psychiatry at the University of Miami Miller School of Medicine, an unbiased observer said that the association between antidepressant use and atherosclerosis had not been a cause-and-effect relationship. Musselman also strongly advises patients not to stop taking antidepressants based on this study. Tuesday The data has been presented, 5 at the American University of Cardiology achieving in New Orleans April. The scholarly study was funded by the U.S. National Institutes of Health.